Orforglipron

Orforglipron (trade name Foundayo; development code LY3502970) is a synthetic nonpeptide small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor. It is chemically distinct from all previously approved GLP-1 receptor agonists, which are modified peptides. Developed originally by Chugai Pharmaceutical and licensed to Eli Lilly in 2018, orforglipron contains no peptide bonds; its complex polycyclic architecture incorporates fluoroarene, indazole, imidazole, pyrazolopyridine, and oxadiazole moieties (molecular formula C₄₈H₄₈F₂N₁₀O₅; MW 882.97 g/mol).

The compound binds within the transmembrane domain core of the GLP-1 receptor at a site distinct from the extracellular orthosteric pocket used by the endogenous GLP-1 peptide and peptide-based drugs such as semaglutide. Structural, mutagenesis, and signaling studies published in Science Translational Medicine confirm this allosteric transmembrane binding mode stabilizes an active receptor conformation that couples efficiently to stimulatory G-proteins (Gs), driving cyclic AMP accumulation. The downstream consequence is glucose-dependent insulin secretion and glucagon suppression in the pancreas — producing glycemic benefit without causing isolated hypoglycemia.

• In hypothalamic and brainstem nuclei, GLP-1 receptor activation reduces appetite and food intake; the FDA label notes that orforglipron reduces body weight with proportionally greater fat mass than lean mass loss. • The absence of peptide bonds confers complete resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, the primary barrier to oral bioavailability for peptide GLP-1 agents. Oral bioavailability is approximately 30–40%, with peak plasma concentrations within 2–4 hours and a terminal half-life of 29–49 hours, enabling once-daily dosing without food or water timing restrictions. Primary elimination is hepatic via CYP3A4.

Orforglipron has been evaluated in a large, phased clinical program culminating in FDA approval (NDA 220934, April 2026) as Foundayo for chronic weight management.

A Phase 1b multiple-ascending-dose study in adults with type 2 diabetes (PMID 37264711) established proof of concept for oral GLP-1 receptor agonism, demonstrating dose-dependent HbA1c and fasting glucose reductions with an acceptable safety profile.

A Phase 2 randomized trial (n = 272 adults with obesity but without diabetes, 36 weeks; NEJMoa2302392, NEJM September 2023) evaluated doses of 12, 24, 36, and 45 mg once daily. Mean weight loss at 36 weeks ranged from −9.4% to −14.7% with orforglipron versus −2.3% with placebo; 46–75% of treated participants achieved ≥10% body weight reduction compared with 9% on placebo. Gastrointestinal events were the principal adverse events.

Phase 3 ATTAIN program: ATTAIN-1 (n = 3,127 adults without diabetes, 72 weeks; NEJMoa2511774, NEJM September 2025) found mean weight loss of 12.4% (~27.3 lbs) at the 36 mg dose versus 2.1% with placebo. At 36 mg, 59.6% of participants lost ≥10% and 39.6% lost ≥15% of body weight. ATTAIN-2 (n = 1,613 adults with T2D and obesity, 72 weeks; published in The Lancet 2025, NCT05872620) demonstrated weight loss of 10.5% at 36 mg versus 2.2% with placebo and HbA1c reduction of approximately 1.8 percentage points; 66.6% of participants on 36 mg reached HbA1c ≤6.5%.

Phase 3 ACHIEVE program for type 2 diabetes: ACHIEVE-1 (n = 559, 40 weeks; NEJMoa2505669) enrolled participants with early T2D managed by diet alone, achieving HbA1c reductions of 1.3–1.6 percentage points from a baseline of 8%. ACHIEVE-2 (n = 962, 40 weeks) compared orforglipron to dapagliflozin 10 mg on background metformin; orforglipron (12 mg and 36 mg) reduced HbA1c by 1.50 and 1.56 percentage points respectively versus 0.81 with dapagliflozin, with weight losses of 5.7% and 6.8% versus 2.4%. A head-to-head trial versus oral semaglutide published in The Lancet reported superior glycemic control and weight reduction for orforglipron.

Across trials, consistent cardiometabolic secondary benefits were observed including reductions in systolic blood pressure, non-HDL cholesterol, and triglycerides. A dedicated cardiovascular outcomes trial, ATTAIN-Outcomes (NCT07241390), is ongoing with primary completion estimated August 2031.

Typical dosage: Clinical trials (daily).

The FDA-approved titration schedule for Foundayo (orforglipron), as reflected in the DailyMed prescribing information (NDA 220934, 2026), begins at 0.8 mg once daily. Dose escalation proceeds with a minimum of 30 days between each increase, advancing through 2.5 mg, then 5.5 mg, then 9 mg, then 14.5 mg, to a maximum of 17.2 mg once daily, as tolerated. Tablets are taken orally at any time of day without food or water restrictions and must be swallowed whole; do not crush or chew.

• Starting dose: 0.8 mg once daily • Escalation steps (minimum 30 days each): 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg • Maximum approved dose: 17.2 mg once daily • With strong CYP3A4 inhibitors: maximum dose reduced to 9 mg daily; avoid strong CYP3A4 inducers; monitor with moderate inducers • Simvastatin dose should not exceed 20 mg daily when co-administered • Oral contraceptives: recommend non-oral or barrier method for 30 days after initiation and after each dose escalation

Note: Clinical trials used higher absolute dose values (up to 36 mg) reflecting an earlier formulation and escalation scheme; the approved commercial product employs a revised dosing scheme with a different absolute mg range.

This information is provided for educational reference only and does not constitute medical advice. Dosing decisions, including initiation, titration, and management of adverse effects, must be made in consultation with a licensed healthcare provider familiar with the patient's full medical history.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Within the Phase 3 ACHIEVE program, orforglipron was evaluated in adults already receiving metformin as background therapy (ACHIEVE-2). It outperformed dapagliflozin on HbA1c reduction and weight loss in this context, establishing a rationale for use atop metformin, the most commonly prescribed first-line diabetes agent.

A separate registered trial (NCT06109311) is evaluating orforglipron added to insulin glargine, with or without background metformin and/or an SGLT2 inhibitor, in adults with type 2 diabetes inadequately controlled on basal insulin. This reflects a clinically relevant question about GLP-1/basal insulin combinations, where the two drug classes have complementary mechanisms (GLP-1 addresses postprandial excursions and weight; basal insulin addresses fasting glucose).

The approved prescribing label explicitly states that orforglipron should not be combined with other GLP-1 receptor agonists (including oral semaglutide), as no additive benefit has been demonstrated and safety has not been established.

No published human data exist on combining orforglipron with dual GIP/GLP-1 agonists (such as tirzepatide), GLP-1/glucagon dual agonists, or investigational triple agonists. Any such combination would be purely speculative and is not supported by clinical evidence at this time.

Orforglipron is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Under investigation

The adverse event profile of orforglipron is dominated by gastrointestinal effects, consistent with the GLP-1 receptor agonist class. In the ATTAIN-1 Phase 3 trial, gastrointestinal events occurred in 60–69% of orforglipron recipients versus 37% with placebo. At the 36 mg dose: nausea 34%, vomiting 24%, constipation 25%, and diarrhea 23%. Approximately 96% of these events were mild to moderate in severity; they occurred primarily during dose escalation and diminished with continued use. Treatment discontinuation due to adverse events was 5.3% (6 mg), 7.9% (12 mg), and 10.3% (36 mg) versus 2.7% with placebo.

Foundayo carries a BOXED WARNING for the risk of thyroid C-cell tumors — a class labeling requirement for GLP-1 receptor agonists. Importantly, orforglipron was not pharmacologically active at the rodent GLP-1 receptor and produced no thyroid tumors in animal studies; however, the FDA determined human relevance has not been ruled out.

Contraindications: personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2); serious hypersensitivity to orforglipron or its excipients; pregnancy (animal studies demonstrated external malformations in rabbits at high exposures; drug detected in rat milk at 3-fold plasma concentrations, and breastfeeding is not recommended).

Warnings and precautions from the label include: acute pancreatitis (discontinue if suspected); severe gastrointestinal reactions (not recommended in gastroparesis); acute kidney injury from dehydration; hypoglycemia risk when combined with insulin or sulfonylureas; serious hypersensitivity including anaphylaxis; diabetic retinopathy complications; acute gallbladder disease (cholecystitis/cholelithiasis); and pulmonary aspiration risk during general anesthesia or deep sedation due to delayed gastric emptying. Hypoglycemia as an isolated event is uncommon given the glucose-dependent mechanism; in an ATTAIN-2 subgroup, plasma glucose below 54 mg/dL was reported in 2% of orforglipron participants versus 0.2% with placebo. The nonpeptide structure eliminates immunogenicity; no anti-drug antibodies have been observed.